Welcome to the REPLACE study

Clinical data indicate that 20–60% of patients with PAH receiving PDE5i do not reach or maintain treatment goals. Switching to riociguat may be a treatment option for these patients. The REPLACE study investigated the efficacy and safety of switching from PDE5i to riociguat compared with remaining on PDE5i in patients with PAH at intermediate risk.

REPLACE key results

The REPLACE study met its primary endpoint. Switching from PDE5i to riociguat resulted in a significantly higher proportion of patients experiencing clinical improvement and significantly lower rates of clinical worsening compared with remaining on PDE5i.

Professor Marius Hoeper

presents the REPLACE study results

On behalf of the REPLACE investigators, Professor Marius Hoeper presents a summary of the findings of the REPLACE study.

Rationale & study design

Learn about the REPLACE study rationale and design

Study results

See the video presentation of the study results and supporting data


Find resources associated with the study, including other riociguat publications

WordPress Video Lightbox Plugin

For healthcare professionals not based in the USA or the UK

This site is intended for healthcare professionals not based in the USA or the UK.

Please confirm that you are a healthcare professional and that you are not based in the USA or the UK